Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Ramucirumab papillary thyroid carcinoma not applicable detail...
RET rearrange Sorafenib papillary thyroid carcinoma sensitive detail...
RET rearrange Ponatinib papillary thyroid carcinoma sensitive detail...
BRAF V600E RO5126766 papillary thyroid carcinoma sensitive detail...
TP53 wild-type APG-115 papillary thyroid carcinoma sensitive detail...
Unknown unknown Lenvatinib papillary thyroid carcinoma not applicable detail...
RET fusion LOXO-292 papillary thyroid carcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01534897 Phase I Dabrafenib Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436 Completed
NCT01709292 Phase II Vemurafenib Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer Active, not recruiting
NCT01723202 Phase II Trametinib + Dabrafenib Dabrafenib Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer Active, not recruiting
NCT02145143 Phase I Vemurafenib Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib Active, not recruiting
NCT02211222 Phase I Lenvatinib An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer Approved for marketing
NCT02702388 Phase II Lenvatinib Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile Recruiting
NCT02973997 Phase II Lenvatinib + Pembrolizumab Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery Recruiting
NCT03002623 Phase II CUDC-907 CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer Terminated
NCT03215095 Phase I Durvalumab RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers Recruiting
NCT03319628 Phase I XMT-1536 First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b Recruiting
NCT03469011 Phase I Imatinib A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer. Recruiting